Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers

[1]  P. Dhawan,et al.  MASTL: A novel therapeutic target for Cancer Malignancy , 2020, Cancer medicine.

[2]  Peter B. McGarvey,et al.  Proteogenomic Characterization of Endometrial Carcinoma , 2020, Cell.

[3]  Sara R. Savage,et al.  Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma , 2020, Cell.

[4]  S. Varambally,et al.  Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers , 2019, Nature Communications.

[5]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2019, Cell.

[6]  Subha Madhavan,et al.  Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities , 2019, Cell.

[7]  C. Creighton,et al.  Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases , 2018, Clinical Cancer Research.

[8]  John E. Scott,et al.  Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2). , 2018, Biochemical and biophysical research communications.

[9]  Ryan Miller,et al.  WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research , 2017, Nucleic Acids Res..

[10]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[11]  Lovelace J. Luquette,et al.  A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. , 2017, Cancer cell.

[12]  B. Tops,et al.  Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines , 2017, Oncotarget.

[13]  Yiling Lu,et al.  Multiplatform-based Molecular Subtypes of Non-Small Cell Lung Cancer , 2016, Oncogene.

[14]  Ronald J. Moore,et al.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.

[15]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[16]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[17]  Subha Madhavan,et al.  The CPTAC Data Portal: A Resource for Cancer Proteomics Research. , 2015, Journal of proteome research.

[18]  Pieter Wesseling,et al.  International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.

[19]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[20]  Adam A. Margolin,et al.  Assessing the clinical utility of cancer genomic and proteomic data across tumor types , 2014, Nature Biotechnology.

[21]  Prahlad T. Ram,et al.  A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.

[22]  Mehdi Mesri,et al.  Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. , 2013, Cancer discovery.

[23]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[24]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[25]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[26]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[27]  C. Sander,et al.  Integrated Analyses of microRNAs Demonstrate Their Widespread Influence on Gene Expression in High-Grade Serous Ovarian Carcinoma , 2012, PloS one.

[28]  Tatsuhiko Tsunoda,et al.  High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway , 2012, Clinical Cancer Research.

[29]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[30]  T. Ørntoft,et al.  Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer , 2009, Clinical Cancer Research.

[31]  W. Weichert,et al.  A prognostic gene expression index in ovarian cancer—validation across different independent data sets , 2009, The Journal of pathology.

[32]  H. Hollema,et al.  Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer , 2009, PLoS medicine.

[33]  Martin M Matzuk,et al.  A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. , 2008, RNA.

[34]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[35]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Anil Potti,et al.  An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Robert Tibshirani,et al.  Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma , 2005, PLoS medicine.

[38]  Wing H Wong,et al.  Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. , 2005, Cancer research.

[39]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[40]  P. Brown,et al.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Cooper,et al.  Protein Kinases as Therapeutic Targets , 2000, Pharmaceutical Research.

[42]  Hong Wang,et al.  Protein profiles associated with survival in lung adenocarcinoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Chad Creighton,et al.  Gene expression patterns define pathways correlated with loss of differentiation in lung adenocarcinomas , 2003, FEBS letters.

[45]  David E. Misek,et al.  Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.

[46]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[47]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[48]  D. Sanger,et al.  Discriminative stimulus properties of chlordiazepoxide and zolpidem. Agonist and antagonist effects of CGS 9896 and ZK 91296 , 1987, Neuropharmacology.

[49]  R. Bush.  The significance of anemia in clinical radiation therapy. , 1986, International journal of radiation oncology, biology, physics.

[50]  B. Austen,et al.  Intramucosal activation of pepsinogens in the pathogenesis of acute gastric erosions and their prevention by the potent semisynthetic amphipathic inhibitor pepstatinyl-glycyl-lysyl-lysine. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[51]  J. Olney,et al.  Monosodium glutamate effects. , 1971, Science.

[52]  H. Kure.  [Maturation of the uterine cervix]. , 1970, Nihon Sanka Fujinka Gakkai zasshi.

[53]  M. Winiker,et al.  [Animal experiments on the caries protective effect of glycerophosphate]. , 1970, Acta medica Academiae Scientiarum Hungaricae.